Tumor Microenvironment: Prospects for Diagnosis and Prognosis of Prostate Cancer Based on Changes in Tumor-Adjacent Stroma

[1]  P. Carroll,et al.  Management of intermediate-risk prostate cancer with active surveillance: never or sometimes? , 2017, Current opinion in urology.

[2]  P. Nelson,et al.  DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes , 2017, Molecular Cancer Research.

[3]  I. Thompson,et al.  Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. , 2017 .

[4]  Alain Bergeron,et al.  Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.

[5]  M. Bisoffi,et al.  Association and regulation of protein factors of field effect in prostate tissues , 2016, International journal of oncology.

[6]  M. Parmar,et al.  STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply , 2016, The Lancet.

[7]  M. Parmar,et al.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.

[8]  Nolan G. Ericson,et al.  Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations , 2016, Molecular Cancer Research.

[9]  U. Ferreira,et al.  Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells , 2015, International braz j urol : official journal of the Brazilian Society of Urology.

[10]  Z. Jia,et al.  Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China , 2015, Oncotarget.

[11]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[12]  J. Lindberg,et al.  Tracking the origin of metastatic prostate cancer. , 2015, European urology.

[13]  J. Nesland,et al.  The prognostic value of reactive stroma on prostate needle biopsy: A population‐based study , 2015, The Prostate.

[14]  M. Bisoffi,et al.  Prostate Field Cancerization: Deregulated Expression of Macrophage Inhibitory Cytokine 1 (MIC-1) and Platelet Derived Growth Factor A (PDGF-A) in Tumor Adjacent Tissue , 2015, PloS one.

[15]  Z. Jia,et al.  Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer , 2015, British Journal of Cancer.

[16]  S. Barni,et al.  Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. , 2014, Clinical genitourinary cancer.

[17]  J. Utikal,et al.  SOX2 and cancer: current research and its implications in the clinic , 2014, Clinical and Translational Medicine.

[18]  L. Klotz,et al.  Active surveillance for clinically localized prostate cancer––A systematic review , 2014, Journal of Surgical Oncology.

[19]  Y. Fukabori,et al.  Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy , 2014, BMC Urology.

[20]  Nengwang Yu,et al.  Mysteries of TGF-β Paradox in Benign and Malignant Cells , 2014, Front. Oncol..

[21]  G. Dotto.  Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. , 2014, The Journal of clinical investigation.

[22]  G. Schulte,et al.  WNT/Frizzled signalling: receptor–ligand selectivity with focus on FZD‐G protein signalling and its physiological relevance: IUPHAR Review 3 , 2014, British journal of pharmacology.

[23]  T. Ahlering,et al.  Generation of “Virtual” Control Groups for Single Arm Prostate Cancer Adjuvant Trials , 2014, PloS one.

[24]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[25]  N. Bhowmick,et al.  A reciprocal role of prostate cancer on stromal DNA damage , 2013, Oncogene.

[26]  M. Kattan,et al.  Adjuvant leuprolide with or without docetaxel in patients with high‐risk prostate cancer after radical prostatectomy (TAX‐3501) , 2013, Cancer.

[27]  Jun Luo,et al.  The mutational landscape of prostate cancer. , 2013, European urology.

[28]  I. Davis,et al.  Cell mates: paracrine and stromal targets for prostate cancer therapy , 2013, Nature Reviews Urology.

[29]  Gerald C. Chu,et al.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.

[30]  D. Tarin.  Role of the host stroma in cancer and its therapeutic significance , 2013, Cancer and Metastasis Reviews.

[31]  F. Guimont,et al.  Mitochondria, prostate cancer, and biopsy sampling error. , 2013, Discovery medicine.

[32]  D. Rowley,et al.  The reactive stroma microenvironment and prostate cancer progression. , 2012, Endocrine-related cancer.

[33]  J. Epstein,et al.  Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling , 2012, Proceedings of the National Academy of Sciences.

[34]  Shizhong Xu,et al.  An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account , 2012, PloS one.

[35]  J. Griffith,et al.  Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization , 2012, The Prostate.

[36]  Z. Jia,et al.  Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse , 2012, PloS one.

[37]  B. Trock,et al.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies , 2012, BJU international.

[38]  P. Kellokumpu-Lehtinen,et al.  Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial , 2012, Prostate Cancer and Prostatic Diseases.

[39]  S Larry Goldenberg,et al.  Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours , 2012, BJU international.

[40]  C. Eng,et al.  Integrated Analysis Reveals Critical Genomic Regions in Prostate Tumor Microenvironment Associated with Clinicopathologic Phenotypes , 2012, Clinical Cancer Research.

[41]  M. Gleave,et al.  Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence , 2011, BJU international.

[42]  I. Thompson,et al.  Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  O. Franco,et al.  Role for stromal heterogeneity in prostate tumorigenesis. , 2011, Cancer research.

[44]  Ming Jiang,et al.  Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. , 2011, Cancer research.

[45]  Nolwenn LeMeur,et al.  Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect , 2010, Clinical Cancer Research.

[46]  Zhenyu Jia,et al.  Diagnosis of prostate cancer using differentially expressed genes in stroma. , 2010, Cancer research.

[47]  L. Klotz,et al.  Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay , 2010, Prostate Cancer and Prostatic Diseases.

[48]  K. Butler,et al.  Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. , 2009, International journal of oncology.

[49]  M. Parmar,et al.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials , 2009, The Lancet. Oncology.

[50]  M. Desai,et al.  The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy , 2009, BJU international.

[51]  Mustafa Ozen,et al.  Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.

[52]  A. D. De Marzo,et al.  Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.

[53]  M. Kawada,et al.  Phthoxazolin A inhibits prostate cancer growth by modulating tumor–stromal cell interactions , 2009, Cancer science.

[54]  G. Haas,et al.  Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer , 2009, BJU international.

[55]  Pierre I Karakiewicz,et al.  An updated catalog of prostate cancer predictive tools , 2008, Cancer.

[56]  S. Hayward,et al.  Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis , 2008, Oncogene.

[57]  R. Matusik,et al.  Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. , 2008, Cancer research.

[58]  M. Srougi,et al.  Prostate Cancer Detection at Rebiopsy After an Initial Benign Diagnosis: Results Using Sextant Extended Prostate Biopsy , 2008, Clinics.

[59]  D. Zaletaev,et al.  Loss of heterozygosity and microsatellite instability in tumor-associated stromal cells and tumor epithelium of prostate cancer , 2008, Molecular Biology.

[60]  Yan Yan,et al.  Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. , 2007, Urology.

[61]  F. Aragona,et al.  Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. , 2007, Urology.

[62]  Qing Nie,et al.  Computational analysis of BMP gradients in dorsal-ventral patterning of the zebrafish embryo. , 2007, Journal of theoretical biology.

[63]  Stephen T. C. Wong,et al.  An automated feedback system with the hybrid model of scoring and classification for solving over‐segmentation problems in RNAi high content screening , 2007, Journal of microscopy.

[64]  K. Williams,et al.  Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. , 2007, Cancer research.

[65]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[66]  Robert D. Cardiff,et al.  Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis , 2005, Cell.

[67]  O. Franco,et al.  Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. , 2005, Cancer research.

[68]  M. Marberger,et al.  Effect of keratinocyte growth factor and activin on cell growth in the human prostatic cancer cell line LNCaP , 2004, World Journal of Urology.

[69]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[70]  M. Ricote,et al.  Immunohistochemical analysis of the IL‐6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate , 2004, The Journal of pathology.

[71]  S. Hayward,et al.  Role of the stromal microenvironment in carcinogenesis of the prostate , 2003, International journal of cancer.

[72]  Hao Fu,et al.  Microarray analysis uncovers retinoid targets in human bronchial epithelial cells , 2003, Oncogene.

[73]  S. Hayward,et al.  Role of stroma in carcinogenesis of the prostate. , 2002, Differentiation; research in biological diversity.

[74]  E. Voest,et al.  Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches , 2002, Molecular and Cellular Endocrinology.

[75]  I. Mowszowicz,et al.  Alterations of expression and regulation of transforming growth factor β in human cancer prostate cell lines , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[76]  S. Hayward,et al.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.

[77]  B. Sleeman,et al.  Mathematical modeling of capillary formation and development in tumor angiogenesis: Penetration into the stroma , 2001 .

[78]  Jonathan I. Epstein,et al.  Predicting Cancer Following a Diagnosis of High-Grade Prostatic Intraepithelial Neoplasia on Needle Biopsy: Data on Men With More Than One Follow-Up Biopsy , 2001, The American journal of surgical pathology.

[79]  M. Marberger,et al.  Insulin-like growth factors and prostate cancer , 2001, World Journal of Urology.

[80]  R W Veltri,et al.  Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. , 2000, Urology.

[81]  Speaker presentations , 2022 .

[82]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[83]  M. Ittmann,et al.  Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  A. Ghahary,et al.  Expression and localization of insulin-like growth factor-1 in normal and post-burn hypertrophic scar tissue in human , 1998, Molecular and Cellular Biochemistry.

[85]  Y. Wong,et al.  Sex hormone‐induced prostatic carcinogenesis in the Noble rat: The role of insulin‐like growth factor‐1 (IGF‐1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer , 1998, The Prostate.

[86]  J. Peluso,et al.  A role for hepatocyte growth factor/scatter factor in regulating normal and neoplastic cells of reproductive tissues. , 1998 .

[87]  Deborah B. Thompson,et al.  Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network , 1997, The Journal of pathology.

[88]  G. Cunha.  Role of mesenchymal‐epithelial interactions in normal and abnormal development of the mammary gland and prostate , 1994, Cancer.

[89]  D. Djakiew.  Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. , 1992, Journal of andrology.

[90]  L. Chung,et al.  Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. , 1989, Endocrinology.

[91]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[92]  L. Chung,et al.  Stromal-epithelial interactions--I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. , 1981, Journal of steroid biochemistry.

[93]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[94]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[95]  Zhenyu Jia,et al.  Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes , 2014, International journal of cancer.

[96]  P. Scardino,et al.  Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. , 2011, The American journal of pathology.

[97]  T. Tammela,et al.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.

[98]  G. Haas,et al.  Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen , 2009, Prostate Cancer and Prostatic Diseases.

[99]  Michael J. Wilson,et al.  Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. , 2008, American journal of clinical pathology.

[100]  L. Chung,et al.  Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. , 2005, The Journal of urology.

[101]  S. Ferrone,et al.  Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. , 2004, Critical reviews in immunology.

[102]  M. Dewhirst,et al.  Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. , 2001, International journal of radiation oncology, biology, physics.

[103]  E. Hay.  An overview of epithelio-mesenchymal transformation. , 1995, Acta anatomica.